FindMyRecallSubscribe
Class II: temporary or reversible health riskCompleted

Dr. Reddy's Laboratories Ranitidine Tablets Recall

Ranitidine Tablets, USP 75 mg

Dr. Reddy's Laboratories, Inc. · Princeton, NJ

Risk level
Class II
Reported by FDA
Nov 13, 2019
Recall ID
D-0178-2020
Check your lot numberHow we source this data

Summary

Dr. Reddy's Laboratories recalled Ranitidine Tablets starting Oct 1, 2019. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0178-2020 on Nov 13, 2019. Reason: CGMP Deviations: Presence of NDMA impurity detected in product. Status: Completed.

Why it was recalled

CGMP Deviations: Presence of NDMA impurity detected in product.

Product description

Ranitidine Tablets, USP 75 mg, NDC 57896-715 (GeriCare) OTC.

Lot numbers, UPCs & expiration codes

Batch Numbers: All lots within expiry.

Where it was sold

Product was distributed to major distributors throughout the United States who may have further distributed the product.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0178-2020
Classification
Class II
Status
Completed
Recall initiated
Oct 1, 2019
FDA report date
Nov 13, 2019
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Dr. Reddy's Laboratories, Inc.

Original FDA data

Every field from FDA enforcement report D-0178-2020, exactly as published.

Show all FDA fields
City
Princeton
State
NJ
Status
Completed
Country
United States
Event ID
83908
Address
107 College Rd E
Code information
Batch Numbers: All lots within expiry.
Postal code
08540-6623
Report date
Nov 13, 2019
Product type
Drugs
Recall number
D-0178-2020
Classification
Class II
Recalling firm
Dr. Reddy's Laboratories, Inc.
Reason for recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Ranitidine Tablets, USP 75 mg, NDC 57896-715 (GeriCare) OTC.
Distribution pattern
Product was distributed to major distributors throughout the United States who may have further distributed the product.
Recall initiation date
Oct 1, 2019
Initial firm notification
Letter
Center classification date
Nov 5, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0178-2020, published Nov 13, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls